Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654160 · ClinicalTrials.gov registry record · Phase 1
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00654160: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00654160 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00654160, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with fluorouracil and leucovorin in treating patients with advanced gastrointestinal cancer.
Interventions
- DRUG fluorouracil
- OTHER pharmacological study
- DRUG leucovorin calcium
- OTHER pharmacogenomic studies
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00654160
The ClinicalTrials.gov registry entry for NCT00654160 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which fluorouracil is the first listed.
NCT00654160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00654160 about?
NCT00654160 is a clinical study titled "Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer". RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: ...
What is the current status of trial NCT00654160?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2008-06. Estimated completion is 2012-12-03.
What interventions are being tested in trial NCT00654160?
The interventions under investigation include: fluorouracil (DRUG), pharmacological study (OTHER), leucovorin calcium (DRUG), pharmacogenomic studies (OTHER), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00654160?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.